Revenue:
- Reported $321.39 million in Q1 2026, down 4.40% YoY and 2.78% QoQ.
Gross Profit:
- $180.47 million with a gross profit margin of 56.15%, an increase from previous quarters, indicating moderate improvements in cost management.
Operating Income:
- Increased 38.69% YoY to $55.14 million, but remained down 22.71% QoQ, reflecting improved operational efficiency despite revenue challenges.
Net Income:
- Reported net income of $34.03 million, down by 11.32% YoY and significantly down 41.31% QoQ, highlighting a concerning trend.
EPS:
- Reported earnings per share at $0.71, a decline of 5.69% YoY and 39.55% QoQ.
These metrics underscore a complex financial positioning for Haemonetics, with operational improvements somewhat masked by overall declines in revenue and profitability. Investors should note the significant fluctuations in performance and their implications for future quarters.